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Anticancer drugs act against abnormal proteins in cancer cells and present a large treatment effect. However, they are often limited by their systemic toxicities and side effects (1) . Therefore, targeting ability is an important factor for the development of drug delivery systems (DDS). To attain pinpoint delivery to target cells, studies have extensively focused on fusing targeting molecules with the drug itself (2) or on modifying the surface of the DDS carrier (3, 4) . As the targeting molecules, binding molecules such as antibodies (5), peptides (6) and aptamers (7) are often used.
As a binding protein, the affibody is an attractive molecule. An affibody is a small molecule that is based on the Z-domain derived from Staphylococcus aureus protein A (8) . As a type of affibody, Z HER2 has the ability to bind to human epidermal growth factor receptor-related 2 (HER2) that is a type 2 epidermal growth factor receptor and is expressed on the surface of breast cancer cells and ovarian cancer cells (9, 10) . Since natural ligands against HER2 have yet to be found in nature (11) , Z HER2 has been used as an alternative molecular probe to diagnose (12) or target HER2-expressing cells (13) . In addition, various other types of affibodies such as Z WT , Z 440 and Z 955 can be used as the binding molecules to the Fc regions of immunoglobulin G, insulin-like growth factor-1 receptor and epidermal growth factor receptor, respectively (8, 14, 15) .
Hepatitis B virus (HBV) core (HBc) protein has been studied for developing viral genome-free particles as DDS carriers. The HBc is a 183-aa protein and assembles spontaneously into icosahedral capsid-like particles comprising 180240 subunits (16) . The important feature of HBc is to transiently dissociate and re-associate in the presence or absence of denaturants, thereby enabling it to enclose molecules such as drugs (17) . In addition, the HBc can be produced in large quantities, because it can be expressed in Escherichia coli (18) . The original HBc has been used as a permeable particle because it has the ability to bind to every cell (16), which is caused by an arginine-rich domain (150183 aa) that recognizes the cell surface heparan sulphate proteoglycan with an electrostatic interaction (19) . Additionally, foreign molecules (e.g. green fluorescence protein) have been successfully displayed on the surface of a HBc particle without drastically altering its structure via insertion into the 7881 aa position of the original HBc core protein (20) .
HBc deletion mutant lacking arginine-rich domain (ÁHBc) consisting of the first 149 aa residues of a core protein was developed as a deletion mutant lacking a non-specific binding ability (21) . The ÁHBc particle is far more suitable for a DDS capsule than the original HBc because of the particle's capacity to incorporate drugs (22) and the avoidance of host-derived RNA/ DNA-binding functions (21) . However, despite the successful development of the ÁHBc particle, there have been no reports of a binding-molecule-fused ÁHBc.
In the present study, we developed a concept for constructing a DDS carrier that is based on the ÁHBc particle and that can specifically recognize target cancer cells. By genetically inserting a Z HER2 affibody between the 78 and 81 aa of a ÁHBc core protein, the engineered particle (Z HER2 -ÁHBc) specifically bound to HER2-expressing breast cancer cells.
Materials and Methods

Construction of plasmids for the expression of core particles
The plasmids for expression of HBc, ÁHBc and Z HER2 -ÁHBc were constructed as described later. 
Expression of core particles in E. coli
The plasmids for expression of HBc, ÁHBc and Z HER2 -ÁHBc were transformed into E. coli BL21. The culture of E. coli BL21 carrying each plasmid was diluted with 1 l of fresh LB medium (1% tryptone, 0.5% yeast extract, 0.5% NaCl) in the presence of 100 mg/ml ampicillin and grown to OD 600 ¼ 0.7 at 37 C and a shaking speed of 150 rpm. The culture was induced by adding isopropyl-bthiogalactopyranoside to a final concentration of 0.1 mM at 25 C overnight. Cells were then collected at 3,000 rpm and 4 C for 15 min.
Purification of core particles
To purify core particles fused with a His6-tag, we followed the procedure described by Wizemann and von Brunn (18) with minor modifications. Briefly, the cell pellet was re-suspended in 50 ml of lysis buffer (pH 8.0) (50 mM TrisHCl, 100 mM NaCl, 5 mM EDTA, 0.2% Triton X-100, 10 mM b-mercaptethanol). The cells were lysed on ice by three cycles of sonication for 1 min each with 2-min intervals to avoid heating of the material. The supernatant was removed by centrifugation at 15,000 rpm and 4 C for 30 min. The core particles in the pellet were washed in 50 ml of lysis buffer and collected by centrifugation at 12,000 rpm and 4 C for 15 min twice. The pellet containing E. coli proteins was dissolved in 50 ml of dissociation buffer (pH 9.5) (4 M urea, 200 mM NaCl, 50 mM sodium carbonate, 10 mM b-mercaptethanol) by overnight incubation in an ice-cold water bath. Then, the soluble fraction was separated by centrifugation at 15,000 rpm and 4 C for 20 min. Contaminating proteins were separated from the core particle proteins using Ni 2+ -chelate affinity chromatography. A column with 10 ml of Ni 2+ -chelate agarose (Nacalai Tesque, Kyoto, Japan) was pre-equilibrated with a 5-fold volume of dissociation buffer. The prepared sample was loaded into a column and washed with 30 ml of dissociation buffer. Then, bound proteins were eluted with 30 ml of elution buffer (pH 9.5) (4 M urea, 200 mM NaCl, 50 mM sodium carbonate, 10 mM b-mercaptethanol, 1 M imidazole). The eluate was fractionated in 1-ml aliquots. The aliquots of each fraction were subjected to sodium dodecyl sulphatepolyacrylamide gel electrophoresis (SDSPAGE) and stained with Coomassie brilliant blue to analyse their purity. The proteins of purified fractions were polymerized to core particles by the removal of the urea in a polymerization buffer (pH 7.0) (500 mM NaCl, 50 mM TrisHCl, 0.5 mM EDTA).
SDSPAGE and western blotting
The expression of each core monomer was confirmed by western blotting. The purified core particles were analysed by SDSPAGE and electrotransferred onto a polyvinilidene fluoride membrane. For the detection of the His6-tag, rabbit anti-6-His antibodies (Bethyl Laboratories, Montgomery, TX, USA) were used as a primary antibody for immunoblotting, followed by anti-rabbit antibodies conjugated with alkaline phosphatase (Promega, Madison, WI, USA) used as a second antibody. For the detection of Z protein, Goat anti-protein A antibodies (Rockland Immunochemicals Inc., Gilbertsville, PA, USA) were used as the primary antibody for immunoblotting, followed by anti-goat antibodies conjugated with alkaline phosphatase (Promega) used as the second antibody. The membrane was stained with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium (Promega).
Atomic force microscopy analysis of purified core particles A gold chip (100-nm thickness of Au wafer; KST world, Fukui, Japan) was covered with 200 ml of solution containing core particles at room temperature for 1 h. The gold chip was then washed with 10 ml of polymerization buffer. After washing, the core particles adsorbed onto the surface of the gold chip were measured using an SPA400-Nanonavi atomic force microscopy unit (SII Nanotechnology Inc., Chiba, Japan) with a cantilever (BL-RC150VB-C1 from Olympus, Tokyo, Japan) at 0.8 kHz scan speed according to the manufacturer's procedure.
Dynamic light scattering analysis of purified core particles The size of the purified core particles was determined by dynamic light scattering using a Zetasizer Nano ZS (Malvern Instruments Ltd, Worcestershire, UK), following the manufacturer's procedure.
Cell culture SKBR3 cells (human breast carcinoma) were maintained in RPMI 1640 medium supplemented with 10% (v/v) foetal bovine serum (FBS) at 37 C in 5% CO 2 . MCF-7 cells (human breast carcinoma) and HeLa cells (human cervical carcinoma) were maintained in Dulbecco's modified Eagle medium supplemented with 10% FBS at 37 C in 5% CO 2 .
Flow cytometric evaluation
Purified core particles were reacted with Alexa Fluor 488 Succinimidyl Esters (Invitrogen Life Technologies, Carlsbad, CA, USA) (2.6 mol equiv) in phosphate-buffered saline for 1 h at room temperature. The mixture then was dialysed against polymerization buffer overnight to remove free Alexa Fluor 488. Approximately 2 Â 10 5 of SKBR3, MCF-7 and HeLa cells were seeded in individual 12-well plates. After washing with serum-free medium, indicated volumes of Alexa Fluore 488-labelled core particles were added to the medium, each of which was adjusted to a volume of 1 ml, followed by culturing of the cells for 1 h. After washing with serum-free medium twice, the cells were incubated with FBS-containing medium for 2 h. Cells were suspended into a sheath solution and subjected to a BD FACSCanto II flow cytometer equipped with a 488-nm blue laser (BD Biosciences, San Jose, CA, USA). The green fluorescence signal was collected through a 530/30-nm band-pass filter. The data were analysed using the BD FACSDiva software v5.0 (BD Biosciences).
Confocal laser scanning microscopy observation
Approximately 5 Â 10 4 of SKBR3, MCF-7 and HeLa cells were seeded in individual 35-mm glass-bottom dishes. After washing with serum-free medium, Alexa Fluore 488-labelled core particles (10 mg/ml) were added and then cells were cultured for 1 h. After washing with serum-free medium twice, the cells were incubated with FBS-containing medium for 2 h. The cells were observed using a LSM 5 PASCAL laser scanning confocal microscope (Carl Zeiss, Oberkochen, Germany) equipped with a 63-fold oil immersion objective lens with excitation by the 488-nm line of an argon laser and emission collection by a 505-nm long-pass filter.
Results and Discussion
Expression of core proteins and formation of particles As shown in Fig. 1 , we first constructed the plasmid to express the His6-tag-fused HBc, which consisted of 183 aa residues of full-length core proteins. To eliminate the non-specific binding property of a core protein, we constructed the plasmid to express a ÁHBc consisting of 149 aa residues by deleting the corresponding sequence to the C-terminal arginine-rich domain (Fig. 1) . Finally, we constructed the expression plasmid for Z HER2 -ÁHBc, in which a Z HER2 affibody molecule was inserted between the 78 and 81 aa positions of the ÁHBc (Fig. 1) . As described in the 'Materials and Methods' section, we introduced these plasmids into E. coli and produced each kind of HBc particle.
First, to check the expression and purification of each core protein, we performed western blot analysis with anti-His6 antibody. Since three His6-specific bands appeared at each desired position (HBc, 21 kDa; ÁHBc, 17 kDa and Z HER2 -ÁHBc, 24 kDa), successful expression and purification of the core proteins were confirmed (Fig. 2, left) . When using anti-protein A antibody that can specifically bind to the Z-derived affibodies, we detected the single band only for Z HER2 -ÁHBc (24 kDa), as expected (Fig. 2,  right) . Furthermore, secondary structural formation of each core protein was confirmed by circular dichroism spectra analysis (data not shown).
Second, to examine whether each core proteinformed particle could be attributed to the capsid-like structure, we analysed the purified core proteins by dynamic light scattering (Fig. 3) and atomic force microscopy (Fig. 4) . Two measurement analyses suggested similar results, and it was strongly supported that every core protein showed same particle-like structure that was $50 nm in diameter. According to previously reported for wild-type HBc particles analysis (20, 21) , it was assumed that the deletion of the arginine-rich domain and the insertion of the Z HER2 affibody did not affect the self-assembly of the engineered core proteins. Fig. 1 Schematic representations of constructed core proteins (HBc, "HBc and Z HER2 -"HBc). Wild-type HBc core protein consisted of an assembly domain (grey prismatic body) and an arginine-rich domain (white prismatic body). For ÁHBc core protein, the arginine-rich domain (150183 aa) was deleted. For the Z HER2 -ÁHBc core protein, Z HER2 affibody (diagonal prismatic body) was inserted at the XhoI and XbaI sites between 78 and 81 aa. For all constructs, His6-tag (black prismatic body) was fused to the C-termini.
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(anti-His6 antibody)(anti-protein A antibody) Fig. 2 Western blotting analyses of purified core particles. Purified samples (HBc, ÁHBc and Z HER2 -ÁHBc) were subjected to SDSPAGE followed by immunoblotting using anti-His6 antibody (for His6-tag, left image) and anti-protein A antibody (for Z HER2 affibody, right image).
Hepatitis B core particle targeting HER2-expressing cells
Examination of the ability of a Z HER2 -DHBc particle to recognize HER2-expressing breast cancer cells Next, to evaluate the binding ability to HER2-expressing breast cancer cells, we labelled the particles with Alexa Fluor 488. Then, each kind of particle was added to two types of HER2-positive human breast cancer cells (SKBR3, expressing an abundant amount of HER2, and MCF-7, expressing a tiny amount of 
HER2
) and a HER2-negative human cervical cancer cell (HeLa) at several concentrations. After 3 h of incubation, we measured the fluorescence intensity of these cells by FACS.
As shown in Fig. 5A , the addition of a wild-type HBc particle caused a dose-dependent increase in fluorescence for all three kinds of cancer cells (SKBR3, MCF-7 and HeLa), indicating that the original HBc particle binds to the cells in a non-specific manner. The addition of a ÁHBc particle did not exhibit fluorescence for all three cells, supporting the theory that the deletion of the arginine-rich domain can cancel the non-specific binding ability of the original HBc (Fig. 5B) . In contrast, the addition of a Z HER2 -ÁHBc particle promoted an apparent fluorescence for SKBR3 cells in a dose-dependent manner (white bars), whereas it never exhibited fluorescence for the HeLa cells (black bars) (Fig. 5C) . Additionally, the addition of Z HER2 -ÁHBc to MCF-7 showed a weaker fluorescence than in the case of SKBR3 (Fig. 5C, grey bars) . These results indicate that Z HER2 -ÁHBc specifically recognized HER2-expressing breast cancer cells and that the binding amount of Z HER2 -ÁHBc differed in accordance with the HER2 expression levels in the cells.
Finally, to visually observe the binding ability of these particles to the cells, Alexa Fluor 488-labelled core particles were added into the cell cultures (SKBR3, MCF-7 and HeLa) to give a final concentration of 10 mg/ml. After 3 h of incubation, the cells were observed using a confocal laser scanning microscope (Fig. 6) . These results were consistent with the results of the FACS analyses (Fig. 5) , demonstrating that the Z HER2 -ÁHBc particle has the ability to specifically bind to HER2-expressing breast cancer cells.
In conclusion, we developed a HBc particle displaying a Z HER2 affibody that specifically recognizes HER2-expressing breast cancer cells. It would be possible to incorporate drugs into Z HER2 -HBc particles by using the dissociation and association mechanism regulated by salt concentration (24) or urea denaturant (18) , or by fusing peptidic drugs to C-terminal tail of core protein (22) . By inserting other types of affibody Hepatitis B core particle targeting HER2-expressing cells molecules to the ÁHBc, these engineered HBc core particles could be used as pinpoint carriers to target various kinds of cancer cells.
